Coegin Pharma (NGM:COEGIN) Scaled Net Operating Assets: 0.20 (As of Mar. 2026)


NGM:COEGIN Coegin Pharma NGM:COEGIN
30 GF Score
Price kr3.63
! 2 Warning Signs
View Full Analysis

What is Coegin Pharma Scaled Net Operating Assets?

Coegin Pharma NGM:COEGIN +5.22% 30 Scaled Net Operating Assets is 0.20 as of Mar. 2026. GuruFocus rates NGM:COEGIN with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Coegin Pharma's operating assets for the quarter that ended in Mar. 2026 was kr4.94 Mil. Coegin Pharma's operating liabilities for the quarter that ended in Mar. 2026 was kr2.24 Mil. Coegin Pharma's Total Assets for the quarter that ended in Dec. 2025 was kr13.34 Mil. Therefore, Coegin Pharma's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.20.


Coegin Pharma Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Coegin Pharma's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coegin Pharma Scaled Net Operating Assets Chart

Coegin Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only -0.29 0.57 0.04 0.36 -0.12

Coegin Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.15 0.24 -0.23 0.20

NGM:COEGIN vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Coegin Pharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coegin Pharma Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coegin Pharma's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Coegin Pharma's Scaled Net Operating Assets falls into.


NGM:COEGIN
30GF Score
Coegin Pharma NGM:COEGIN
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coegin Pharma Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Coegin Pharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(5.42-8.6)/27.04
=-0.12

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=13.343 - 7.923
=5.42

Coegin Pharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(4.943-2.237)/13.343
=0.20

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=14.209 - 9.266
=4.943

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.237 - 0 - 0
=2.237

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.20 mean?
Coegin Pharma (NGM:COEGIN) has a Scaled Net Operating Assets of 0.20 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Coegin Pharma and its competitors.
Is Coegin Pharma's Scaled Net Operating Assets too high?
Coegin Pharma's current Scaled Net Operating Assets is 0.20. Overall, Coegin Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's Scaled Net Operating Assets compare to VRTX and REGN?
Coegin Pharma's Scaled Net Operating Assets of 0.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Coegin Pharma and its competitors. Coegin Pharma's current Scaled Net Operating Assets is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current Scaled Net Operating Assets of 0.20. The current Scaled Net Operating Assets is 0.20. Coegin Pharma's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current Scaled Net Operating Assets is 0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coegin Pharma Business Description

Other Exchanges 7Z6:Germany
Address c/o Medicon Village, Lund, SWE, 223 81
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
30GF Score

Get the complete analysis for NGM:COEGIN

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.63
Price